Gossamer Bio, Inc. (NASDAQ:GOSS) to Post Q1 2025 Earnings of ($0.20) Per Share, Wedbush Forecasts

Gossamer Bio, Inc. (NASDAQ:GOSS) – Wedbush issued their Q1 2025 EPS estimates for shares of Gossamer Bio in a report released on Wednesday, May 8th. Wedbush analyst L. Chico anticipates that the company will post earnings per share of ($0.20) for the quarter. Wedbush has a “Outperform” rating and a $4.00 price target on the stock. The consensus estimate for Gossamer Bio’s current full-year earnings is ($0.46) per share. Wedbush also issued estimates for Gossamer Bio’s Q2 2025 earnings at ($0.21) EPS, Q3 2025 earnings at ($0.21) EPS, Q4 2025 earnings at ($0.20) EPS and FY2026 earnings at ($0.89) EPS.

Gossamer Bio (NASDAQ:GOSS) last announced its quarterly earnings results on Tuesday, March 5th. The company reported ($0.21) earnings per share (EPS) for the quarter, meeting the consensus estimate of ($0.21).

Other equities analysts also recently issued reports about the stock. HC Wainwright reaffirmed a “buy” rating and issued a $10.00 target price on shares of Gossamer Bio in a research note on Monday, May 6th. The Goldman Sachs Group reduced their price target on shares of Gossamer Bio from $9.00 to $8.00 and set a “buy” rating for the company in a report on Wednesday, March 6th. Finally, Piper Sandler reiterated an “overweight” rating and issued a $15.00 price target on shares of Gossamer Bio in a report on Wednesday, March 27th. One research analyst has rated the stock with a hold rating and four have assigned a buy rating to the company. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $7.65.

Gossamer Bio Trading Up 1.8 %

Shares of GOSS stock opened at $0.73 on Monday. Gossamer Bio has a 12-month low of $0.45 and a 12-month high of $1.88. The company has a market capitalization of $165.77 million, a P/E ratio of -0.69 and a beta of 1.84. The company has a quick ratio of 7.13, a current ratio of 7.13 and a debt-to-equity ratio of 7.37. The firm has a 50-day moving average price of $1.02 and a 200 day moving average price of $0.94.

Insider Transactions at Gossamer Bio

In other news, CEO Faheem Hasnain sold 23,172 shares of the business’s stock in a transaction on Wednesday, March 27th. The shares were sold at an average price of $1.16, for a total value of $26,879.52. Following the sale, the chief executive officer now owns 120,293 shares of the company’s stock, valued at $139,539.88. The sale was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Insiders have sold a total of 33,620 shares of company stock valued at $39,682 over the last 90 days. 5.00% of the stock is owned by corporate insiders.

Institutional Trading of Gossamer Bio

A number of institutional investors have recently made changes to their positions in GOSS. Bank of New York Mellon Corp lifted its position in shares of Gossamer Bio by 178.0% in the third quarter. Bank of New York Mellon Corp now owns 91,246 shares of the company’s stock worth $76,000 after purchasing an additional 58,428 shares in the last quarter. Financial Advocates Investment Management bought a new stake in Gossamer Bio during the third quarter worth $61,000. Platinum Investment Management Ltd. raised its position in Gossamer Bio by 126.7% during the third quarter. Platinum Investment Management Ltd. now owns 5,357,778 shares of the company’s stock worth $4,462,000 after acquiring an additional 2,994,608 shares in the last quarter. Silverarc Capital Management LLC bought a new stake in Gossamer Bio during the third quarter worth $5,105,000. Finally, Federated Hermes Inc. raised its position in Gossamer Bio by 326.2% during the third quarter. Federated Hermes Inc. now owns 3,994,723 shares of the company’s stock worth $3,328,000 after acquiring an additional 3,057,419 shares in the last quarter. Institutional investors own 81.23% of the company’s stock.

About Gossamer Bio

Gossamer Bio, Inc, a clinical-stage biopharmaceutical company, focuses on developing and commercializing seralutinib for the treatment of pulmonary arterial hypertension (PAH) in the United States. The company is developing GB002, an inhaled, small molecule, platelet-derived growth factor receptor, or PDGFR, colony-stimulatin factor 1 receptor and c-KIT inhibitor, which is in Phase 3 clinical trial for the treatment of PAH.